Please login to the form below

Not currently logged in
Email:
Password:

Actos

This page shows the latest Actos news and features for those working in and with pharma, biotech and healthcare.

Takeda and Zinfandel abandon Alzheimer’s drug

Takeda and Zinfandel abandon Alzheimer’s drug

Piogliazone is sold by Takeda under the Actos brand and was a $4bn-a-year product before losing patent protection in 2011, after which generic versions entered the market.

Latest news

  • NICE backs freer use of SGLT2 inhibitors for diabetes NICE backs freer use of SGLT2 inhibitors for diabetes

    The new guidance allows the drugs to be used first-line for people who cannot tolerate metformin, and in whom sulfonylureas or Takeda's Actos (pioglitazone) are not considered appropriate.

  • Takeda to pay $2.4bn to settle Actos cancer suits Takeda to pay $2.4bn to settle Actos cancer suits

    Takeda to pay $2.4bn to settle Actos cancer suits. Will be one of the largest drug safety settlements in US history. ... Actos (pioglitazone) is licensed to help patients with type II diabetes reduce their sugar levels and has been on the market for more

  • US judge cuts billions from Takeda/Lilly Actos payment US judge cuts billions from Takeda/Lilly Actos payment

    US judge cuts billions from Takeda/Lilly Actos payment. Court rules that companies must now pay damages of $36.8m rather than $9bn. ... Takeda has set up six trials involving Actos to help support the drug's safety.

  • Takeda loses in lawsuit claiming cancer link to Actos Takeda loses in lawsuit claiming cancer link to Actos

    Takeda loses in lawsuit claiming cancer link to Actos. Ordered to compensate woman who claims drug gave her bladder cancer. ... Court documents obtained by Bloomberg suggest Actos has generated more than $16bn in sales since its US launch in 1999.

  • Takeda: No link between Actos and bladder cancer Takeda: No link between Actos and bladder cancer

    Takeda: No link between Actos and bladder cancer. Ten-year study backs safety of diabetes drug. ... statistically significant increased risk of developing bladder cancer among patients who used Actos for two years or more.

More from news
Approximately 7 fully matching, plus 81 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    Ulcer drug lansoprazole and prostate cancer treatment leuprorelin already faced generic competition and before the deal was completed Takeda's diabetes drug Actos (pioglitazone) lost exclusivity in January 2011. ... German authorities quickly followed

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    to its multi-billion dollar main product, the antidiabetic Actos (pioglitazone), in August. ... Actos was withdrawn from the market in Germany and France, but not in the US.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics